If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...

Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...

In October, Intellia reported phase 2 results with NTLA-2002 – which is pitching to become the first approved in vivo CRISPR ...

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

Synthego, a leading supplier of CRISPR solutions, has entered a strategic licensing agreement with global biopharmaceutical company AstraZeneca. This agreement grants Synthego a global license to ...

Imagine a world where the genetic code is as easy to edit as a simple copy-and-paste. This is the reality of CRISPR, a ...